Columbia University Medical Center The Cardiovascular Research Foundation Temporal Improvement in Carotid Stent Outcomes: Achievement of AHA Target Goals.

Slides:



Advertisements
Similar presentations
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
Advertisements

Learn neurology “stroke by stroke.” C.M.Fisher. History Wepfer was the first in 1658, to recognize the significance of carotid obstruction and its relationship.
St Luke’s- Hospital Carotid Intervention Position Statement1.
Is Carotid Stenting an Option for Treatment of Carotid Stenosis? Joint Hospital Surgical Grand Round WH WONG Queen Mary Hospital.
Indications for CAS vs Surgical_Medical Marianne Brodmann Division of Angiology Graz.
FFR vs Angiography for Multivessel Evaluation
Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy Presented by Jay Yadav, MD on behalf of the SAPPHIRE Investigators.
The INTENSIFY study: practical daily effectiveness and tolerance of ivabradine in chronic systolic heart failure in Germany Zugck C, Martinka P, Stöckl.
Asymptomatic Carotid Surgery Trial ACST-2 Collaborators Meeting 2014 Pembroke College, Oxford Is recent coronary stenting a problem (or an opportunity)
Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006 Journal Club Ani Balmanoukian and Peter Benjamin November 9, 2006.
Carotid Endarterectomy versus Stenting: Where do we stand today? Vascular Conference March 23, 2010.
Endovascular Management of Intracranial and Extracranial Atherosclerosis Rishi Gupta, MD Associate Professor of Neurology, Neurosurgery, and Radiology.
Hind Alnajashi. C AROTID ARTERY ANATOMY Common carotid artery Aortic arch Internal carotid MCA ACA Ophthalmic artery. Cervical segment Petrous segment.
What Is Peripheral Vascular Disease? Daniel B. Walsh, M.D. Professor of Surgery, Section of Vascular Surgery Vice-Chair, Department of Sugery Dartmouth-Hitchcock.
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
Epidemiology in HK  Stroke is major cause of morbidity and mortality around the world  4th cause of mortality in HK resulting in >3000 deaths every.
Columbia University Medical Center The Cardiovascular Research Foundation State of the Art Review: Carotid Stenting, Patient Selection, and Clinical Trial.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
A Technical Modification Of Carotid Endarterectomy - Experience With 400 Patients Faik Fevzi Okur Sifa University Cardiovascular Surgery Dept. Izmir /
UPDATE IN CAROTID ARTERY STENTING & STROKE MANAGEMENT Dr. Nikolaos Melas, PhD Vascular and Endovascular Surgeon Military Doctor Associate in 1st department.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
EPIC Trial Evaluating the Use of the FiberNet ® Embolic Protection System In Carotid Artery Stenting Subbarao Myla, MD FACC Principal Investigator & Medical.
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
Medical Management of Claudication: Just Walk it Off!!
: PROFI : A Prospective, Randomized Trial of Proximal Balloon Occlusion vs. Filter Embolic Protection in Patients Undergoing Carotid Stenting Klaudija.
CP CARE Registry Insights to the Future.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
DHHS / FDA / CDRH 1 Panel Questions-Clinical Trial Design 1.Can the data from the investigator-sponsor studies be considered in the evaluation of high.
© 2005 American Academy of NeurologyFebruary 25, 2004 Assessment: Carotid Endarterectomy― An Evidence-Based Review Report of the Therapeutics and Technology.
Antithrombotic Therapy in Peripheral Artery Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions James Hermiller,
Carotid Disease – Stent vs Surgery vs Medical Therapy? Mehdi H. Shishehbor, DO, MPH, PhD Director, Endovascular Services Interventional Cardiology & Vascular.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Influence of Site and Operator Characteristics on.
0 0 Lenox Hill Heart and Vascular Institute of New York SCAI 2005 CAROTID STENTING Clinical Trial Overview SRIRAM S. IYER Lenox Hill Hospital, New York.
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
CAROTID ARTERY ENDARTHERECTOMY &INTERVENTION
Faramarz Amiri MD IUMS.  Severe carotid disease (defined as >80%) 8–12%  Severe carotid disease (>70%) in those with three vessel or left main coronary.
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
(p for noninferiority = 0.01)
UPDATE IN CAROTID ARTERY STENTING & STROKE MANAGEMENT
The CARE Registry is a benchmarking tool for health care providers to measure and improve the care they provide for patients undergoing Carotid Stent.
John P. A. Ioannidis (age 50) Stanford School of Medicine, Athens Graduate, former chairman Department of Hygiene and Epidemiology, University of Ioannina.
William A. Gray, MD DISCLOSURES Consulting Fees
Complex Ostial Disease of the Aortic Arch Vessels
Critical Appraisal of the European CAS Trials
CQC Amit Gossain.
Larissa Registry on CAS and CEA:
Cardiovascular Research Technology Conference (CRT 17)
The Tryton Bifurcation Trial:
Rabih A. Chaer MD Assistant Professor of Surgery
Selecting Patients Best Suited for CEA
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.
Symptomatic vs. Asymptomatic Carotid Endarterectomy
Comparison of carotid endarterectomy and stenting in real world practice using a regional quality improvement registry  Brian W. Nolan, MD, MS, Randall.
Understanding PAD.
Differential outcomes of carotid stenting and endarterectomy performed exclusively by vascular surgeons in the Carotid Revascularization Endarterectomy.
Status Update from ACST-2
National trends in utilization and postprocedure outcomes for carotid artery revascularization 2005 to 2007  Mohammad H. Eslami, MD, James T. McPhee,
Carotid Stenting in Acute Ischemic Stroke Resulting from Tandem Occlusions STEWART WEBER, MD.
Cost-effectiveness of carotid endarterectomy in asymptomatic patients
Preoperative risk factors for carotid endarterectomy: defining the patient at high risk  Amy B Reed, MD, Peter Gaccione, MA, Michael Belkin, MD, Magruder.
Philip P. Goodney, MD, Donald S. Likosky, PhD, Jack L. Cronenwett, MD 
Long-term results of 442 consecutive, standardized carotid endarterectomy procedures in standard-risk and high-risk patients  D. Preston Flanigan, MD,
Predictors of 30-day postoperative stroke or death after carotid endarterectomy using the 2012 carotid endarterectomy-targeted American College of Surgeons.
Antonio V. Sterpetti, MD, Richard D. Schultz, MD, Richard J
Mark A. Mattos, MD, Paul S. van Bemmelen, MD, Lynne D
Emily L. Spangler, MD, MS, Philip P
Transcarotid Artery Revascularization versus Transfemoral Carotid Artery Stenting for Treatment of Carotid Artery Stenosis Patric Liang, MD; Marc L.
Carotid artery stenting has increased rates of postprocedure stroke, death, and resource utilization than does carotid endarterectomy in the United States,
Presentation transcript:

Columbia University Medical Center The Cardiovascular Research Foundation Temporal Improvement in Carotid Stent Outcomes: Achievement of AHA Target Goals in Abbott Vascular Post-Marketing Trials William A. Gray MD, Ronald Fairman MD, Rod Raabe MD, L. Nelson Hopkins MD, Jay S. Yadav MD, Richard Atkinson MD, Mark Wholey MD, Richard Green MD, Stan Barnwell MD. For the CAPTURE Investigators TCT October 20th, 2007 (Washington D.C.)

Carotid Stenting Post-Marketing Studies: Temporal relationships Oct ‘04 Oct ‘06 Oct ‘05 Dec ‘ sites CAPTURE Enrollment completed First Generation Post Approval Study 1 year follow-up to be completed Q sites EXACT Second Generation Post Approval Study Nov ‘05 Mar ‘ sites CAPTURE 2 Enrollment ongoing Temporal Second Generation Post Market Study Apr ‘07

Post-Market Multicenter Study: Quantity Sample sizes EXACT and CAPTURE/CAPTURE 2 were initiated independently by two sponsors (ABT, GDT) and use 2 different device systems (Xact/Emboshield and Acculink/Accunet). Large sample size, large # of sites  Total patients: 8336  4225 patients/144 sites (CAPTURE),  1987 patients/167 sites (CAPTURE 2),  2124 patients/126 sites (EXACT) 8334 total patients Largest prospective, multi-center, neurologically-controlled, independently-adjudicated data set for carotid intervention ever assembled

AHA 1998 CEA Guidance Document Patients With Asymptomatic Carotid Artery Disease For patients with a surgical risk <3% and life expectancy of at least 5 years: Proven indications: Ipsilateral carotid endarterectomy is acceptable for stenotic lesions (<60% diameter reduction of distal outflow tract with or without ulceration and with or without antiplatelet therapy, irrespective of contralateral artery status, ranging from no disease to occlusion [Grade A recommendation]) Biller J, Feinberg WM, Castaldo JE, Whittemore AD, Harbaugh RE, Dempsey RJ, Caplan LR, Kresowik TF, Matchar DB, Toole JF, Easton JD, Adams HP Jr, Brass LM, Hobson RW 2nd, Brott TG, Sternau L. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association Circulation Feb 10;97(5): These recommendations were based, in large part, on the results of the ACAS trial which demonstrated a benefit of CEA over medical Rx with a perioperative stroke and death rate of 2.7% in a low surgical risk cohort under 75 years Surgical endarterectomy has never, to date, demonstrated outcomes consistent with AHA guidelines within a prospective, neurologically-controlled, multi-center, adjudicated critical assessment of high surgical risk patients

CAPTURE 2 and EXACT: All stroke/death and major stroke/death by symptom status Hierarchical Events – Includes only the most serious event for each patient and includes only each patient’s first occurrence of each event. Clinical Studies are not directly comparable by methodology presented. -Data from respective studies are presented for Educational purposes EXACT: n=2124 CAPTURE 2: n=1987 EXACT: n=204 CAPTURE 2: n=197 EXACT: n=1917 CAPTURE 2: n=1788 All patientsSymptomatic Asymptomatic

CAPTURE 2 and EXACT: Asymptomatics 30 day Outcomes by Octogenarian Status Hierarchical Events – Includes only the most serious event for each patient and includes only each patient’s first occurrence of each event Clinical Studies are not directly comparable by methodology presented. -Data from respective studies are presented for educational purposes EXACT: n=1454 CAPTURE 2: n=1372 EXACT: n=463 CAPTURE 2: n=416 <80 years >80 years 3%

CAPTURE 2 and EXACT: Conclusions Ongoing improvement in outcomes in <80 symptomatics, approaching AHA guidelines Ongoing improvement in outcomes in <80 symptomatics, approaching AHA guidelines  Conclusions are limited by small numbers Ongoing improvement in outcomes in <80 asymptomatics, approaching/achieving AHA guidelines Ongoing improvement in outcomes in <80 asymptomatics, approaching/achieving AHA guidelines First-ever demonstration of carotid revascularization in high surgical risk patients with outcomes consistent with AHA guidelines